Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS

Pyxis Oncology (NASDAQ:PYXS) issued its earnings results on Monday. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06, FiscalAI reports. The firm had revenue of $11.04 million during the quarter.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $1.47 on Monday. Pyxis Oncology has a 12 month low of $0.83 and a 12 month high of $5.55. The firm has a market capitalization of $91.52 million, a P/E ratio of -0.92 and a beta of 1.45. The company’s fifty day moving average price is $1.54 and its 200 day moving average price is $2.52.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds have recently made changes to their positions in the company. Laurion Capital Management LP increased its position in shares of Pyxis Oncology by 32.3% during the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock worth $5,516,000 after purchasing an additional 1,170,505 shares in the last quarter. Vanguard Group Inc. grew its stake in Pyxis Oncology by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after buying an additional 14,566 shares during the last quarter. Jane Street Group LLC increased its position in Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after buying an additional 482,310 shares during the period. Renaissance Technologies LLC increased its position in Pyxis Oncology by 26.4% during the fourth quarter. Renaissance Technologies LLC now owns 728,380 shares of the company’s stock worth $838,000 after buying an additional 152,044 shares during the period. Finally, Bank of America Corp DE lifted its stake in Pyxis Oncology by 2,690.9% in the third quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock valued at $1,367,000 after buying an additional 593,853 shares during the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on PYXS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Royal Bank Of Canada decreased their price objective on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, December 18th. Stephens increased their target price on Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a report on Monday, November 24th. HC Wainwright raised their price target on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.20.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.